---
title: "Sarepta 报告其基因疗法出现第二例死亡病例"
description: "Sarepta Therapeutics 公司报告其基因疗法出现第二例死亡病例，一名接受 Elevidys 治疗的患者因急性肝衰竭去世。三个月前，另一名十几岁男孩也因相同治疗死亡。两例均为杜氏肌营养不良症且无法行走的患者。公司已暂停相关临床试验，并停止向此类患者提供该药物，正在考虑加强免疫抑制方案。"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/244583352.md"
published_at: "2025-06-15T13:56:21.000Z"
---

# Sarepta 报告其基因疗法出现第二例死亡病例

> Sarepta Therapeutics 公司报告其基因疗法出现第二例死亡病例，一名接受 Elevidys 治疗的患者因急性肝衰竭去世。三个月前，另一名十几岁男孩也因相同治疗死亡。两例均为杜氏肌营养不良症且无法行走的患者。公司已暂停相关临床试验，并停止向此类患者提供该药物，正在考虑加强免疫抑制方案。

Sarepta Therapeutics 公司称，又有一名接受其罕见肌肉疾病基因疗法治疗的患者因急性肝衰竭死亡。该公司表示，这起死亡事件发生在一名接受一次性治疗药物 Elevidys 的患者身上，而三个月前，一名十几岁男孩在接受该治疗后死亡。两起病例均发生在患有杜氏肌营养不良症且无法行走的患者身上。该公司已暂停一项临床试验，停止向无法行走的患者运送该药物，并正在考虑为这些患者加强免疫抑制方案。

### Related Stocks

- [SRPT.US - Sarepta医疗](https://longbridge.com/zh-CN/quote/SRPT.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| BUZZ-Sarepta rises on NZ regulatory nod to start Huntington's disease trial | Sarepta Therapeuticsshares rose 3% to $20.92 in premarket trading after receiving regulatory approval in New Zealand to  | [Link](https://longbridge.com/zh-CN/news/274824082.md) |
| Forecasting The Future: 8 Analyst Projections For Sarepta Therapeutics | During the last three months, 8 analysts evaluated Sarepta Therapeutics (NASDAQ:SRPT), showing a range of bullish to bea | [Link](https://longbridge.com/zh-CN/news/272548848.md) |
| Tempered Growth Outlook and Heightened Regulatory Risk Drive Sell Rating on Sarepta Therapeutics | Needham analyst Gil Blum has reiterated a Sell rating on Sarepta Therapeutics (SRPT) due to concerns over its growth out | [Link](https://longbridge.com/zh-CN/news/272438221.md) |
| Sarepta Therapeutic Q4 prelim net product revenue misses estimates | Sarepta Therapeutics reported preliminary Q4 net product revenue of $369.6 million, missing analyst estimates of $382.07 | [Link](https://longbridge.com/zh-CN/news/272301526.md) |
| JPM26: Sarepta CEO touts “avalanche of Elevidys data” amid 2025 safety woes | Sarepta's CEO Douglas Ingram presented at the J.P. Morgan Healthcare Conference, discussing the challenges faced by Elev | [Link](https://longbridge.com/zh-CN/news/272413649.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。